Navigation Links
Platelet Incubator 3603

ProductsPlatelet Incubator 3603
Company ThermoFisher Scientific
Item Platelet Incubator 3603
Features 
  • 2 solid, roll-out shelves
Description Platelet incubators hold rotators and agitators for continual mixing. Incubator temperature can be set at 22C (71F) or controlled from 15C to 40C (59F to 104F). Uniformity is within 0.5C from top to bottom. Recorder is standard on all models. All platelet incubators are CSA Certified.
Info ThermoFisher Scientific
Web site: http://www.thermo.com
Web site: http://www.thermofisher.com/global/en/home.asp

Related medicine products :

1. Autologous Platelet Gel
2. Platelet Incubator TPSRI-32
3. Platelet Incubator TPSRI-16
4. Platelet Incubator 3606
5. Platelet Incubator 3609
6. i. Series Floor Model Platelet Incubator PC2200i
7. Platelet Incubator 3612
8. i. Series Floor Model Platelet Incubator PC4200i
9. i. Series Floor Model Platelet Incubator PC3200i
10. Horizon Series Floor Model Platelet Incubator PC3200h
11. Horizon Series Floor Model Platelet Incubator PC2200h
Breaking Medicine News(10 mins):Health News:Blood Thinner Combos Risky for Heart Attack Patients 2Health News:Centegra Expands H1N1 Vaccines to General Public 2Health News:Centegra Expands H1N1 Vaccines to General Public 3Health News:Centegra Expands H1N1 Vaccines to General Public 4Health News:Do Charitable Gift Donations Make a Difference? 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 4Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 5Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 6Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 7Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 8Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 9Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 10Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 11Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 12Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 13Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 14Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 15Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 16Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 2Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 3Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 4Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 5Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 6
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Verizon Health Care Experts to Address 2009 Connected Health Symposium in Boston on Oct 21 59823 1Verizon Health Care Experts to Address 2009 Connected Health Symposium in Boston on Oct 21 59823 2Indiana Home Health Agency Pays Nearly 242 Million to Settle False Claims Act Allegations 59819 1Hologic to Present at Citis 2009 Sixth Annual Small Mid Cap Conference 5609 1